THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY

Detalhes bibliográficos
Autor(a) principal: Borges, Filipe
Data de Publicação: 2022
Outros Autores: Marques, Ricardo, Nascimento, Isabel, Raimundo, Luísa, Portugal, Jorge, Costa, Paulo Matos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.34635/rpc.862
Resumo: Background. The ideal surgical strategy to multinodular goiter (MNG) is currently still matter of discussion. Thyroid auto- immunity is a well-known risk factor for hypothyroidism and could play a role in MNG’s physiopathology. Objective. Assess thyroid auto-immunity as a risk factor for MNG recurrence. Materials and Methods. Retrospective analysis of a 5-year (January 2012 – December 2016) prospective database of all patients submitted to hemythyroidectomy for MNG. Variables: age, gender, preoperative diagnosis, anti-peroxidase and anti-thyroglobulin antibodies (anti-TPO and anti-Tg); postoperative L-thyroxin therapy, MNG recurrence, contralateral thyroidectomy. MNG recurrence was defined as the need for complementary contralateral lobectomy, or the appearance of new nodules, or an increase in size of at least 50% of the nodules in the remnant lobe. Results. 82 patients included. Median follow-up time of 49 months [33 –88]. Thyroid auto-immunity (anti-TPO and/or anti-Tg) was present in 26% of the patients. 39% of the patients required replacement postoperative L-thyroxin therapy. Recurrence of MNG was observed in 15,2% of the patients but none required contralateral thyroidectomy. Univariate analysis did not show a statistical significant relationship between thyroid autoimmunity and MNG recurrence (p – 0, 461). Discussion / Conclusion. Thyroid autoimmunity dos not seem to represent a risk factor for MNG recurrence after hemythyroidectomy. This surgical approach was effective, with a low recurrence rate. Also the clinical impact of such recurrence was low with no patient needing contralateral resection.
id RCAP_c923b4c153bdec243bc391b1c579054e
oai_identifier_str oai:revista.spcir.com:article/862
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMYAUTO-IMUNIDADE TIROIDEIA COMO FACTOR DE RISCO PARA RECORRÊNCIA DE BÓCIO MULTINODULAR APÓS LOBECTOMIABackground. The ideal surgical strategy to multinodular goiter (MNG) is currently still matter of discussion. Thyroid auto- immunity is a well-known risk factor for hypothyroidism and could play a role in MNG’s physiopathology. Objective. Assess thyroid auto-immunity as a risk factor for MNG recurrence. Materials and Methods. Retrospective analysis of a 5-year (January 2012 – December 2016) prospective database of all patients submitted to hemythyroidectomy for MNG. Variables: age, gender, preoperative diagnosis, anti-peroxidase and anti-thyroglobulin antibodies (anti-TPO and anti-Tg); postoperative L-thyroxin therapy, MNG recurrence, contralateral thyroidectomy. MNG recurrence was defined as the need for complementary contralateral lobectomy, or the appearance of new nodules, or an increase in size of at least 50% of the nodules in the remnant lobe. Results. 82 patients included. Median follow-up time of 49 months [33 –88]. Thyroid auto-immunity (anti-TPO and/or anti-Tg) was present in 26% of the patients. 39% of the patients required replacement postoperative L-thyroxin therapy. Recurrence of MNG was observed in 15,2% of the patients but none required contralateral thyroidectomy. Univariate analysis did not show a statistical significant relationship between thyroid autoimmunity and MNG recurrence (p – 0, 461). Discussion / Conclusion. Thyroid autoimmunity dos not seem to represent a risk factor for MNG recurrence after hemythyroidectomy. This surgical approach was effective, with a low recurrence rate. Also the clinical impact of such recurrence was low with no patient needing contralateral resection.Introdução. A abordagem cirúrgica ideal para o tratamento do bócio multinodular (BMN) é ainda alvo de debate. A presença de auto-imunidade anti-tiroideia é um fator de risco conhecido para hipotiroidismo, podendo desempenhar um papel na fisiopatologia do BMN. Objectivo. Avaliar a auto-imunidade anti-tiroideia como fator de risco de recidiva de BMN. Métodos. Análise retrospectiva de base de dados prospectiva de todos os doentes submetidos a lobectomia tiroideia por BMN durante 5 anos (Janeiro de 2012 – Dezembro 2016). Variáveis analisadas: idade, sexo, diagnóstico pré-operatório; anticorpos anti-peroxidase (Ac TPO); anticorpos anti-tiroglobulina (Ac TG); hipotiroidismo pós-operatório; recidiva de BMN e necessidade de totalização de tiroidectomia. A recidiva foi definida como o aparecimento de novos nódulos; crescimento de > 50% de nódulos prévios ou a necessidade de totalização. Resultados. Amostra de 82 doentes; 68 mulheres e 14 homens; mediana de idade de 56,5 anos [28 – 82]. Tempo médio de follow up de 79 meses. 26% apresentaram auto-imunidade (Ac TPO ou Ac TG positivos) pré-operatoriamente.  39% necessitaram de levotiroxina pós-operatoriamente. Taxa de recidiva de 15,2%; nenhum doente necessitou de totalização. A análise univariada da relação entre auto-imunidade e recidiva foi feita através do teste de Fischer, não tendo significado estatístico (p – 0, 461). Discussão / Conclusão. A auto-imunidade anti-tiroideia não aparenta ser fator de risco para recidiva de BMN em doentes submetidos a lobectomia tiroideia. A lobectomia foi uma alternativa eficaz, com baixa taxa de recidiva, não tendo sido registado nenhum caso de necessidade de totalização.Sociedade Portuguesa de Cirurgia2022-12-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.34635/rpc.862https://doi.org/10.34635/rpc.862Revista Portuguesa de Cirurgia; No 53 (2022): December 2022; 23-26Revista Portuguesa de Cirurgia; No 53 (2022): December 2022; 23-262183-11651646-6918reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://revista.spcir.com/index.php/spcir/article/view/862https://revista.spcir.com/index.php/spcir/article/view/862/646Copyright (c) 2022 Revista Portuguesa de Cirurgiainfo:eu-repo/semantics/openAccessBorges, FilipeMarques, RicardoNascimento, IsabelRaimundo, LuísaPortugal, JorgeCosta, Paulo Matos2024-03-14T22:05:40Zoai:revista.spcir.com:article/862Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:00:57.036122Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
AUTO-IMUNIDADE TIROIDEIA COMO FACTOR DE RISCO PARA RECORRÊNCIA DE BÓCIO MULTINODULAR APÓS LOBECTOMIA
title THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
spellingShingle THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
Borges, Filipe
title_short THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
title_full THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
title_fullStr THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
title_full_unstemmed THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
title_sort THYROID AUTO-IMMUNITY AS A RISK FACTOR FOR RECURRENT MULTINODULAR GOITER AFTER HEMITHYROIDECTOMY
author Borges, Filipe
author_facet Borges, Filipe
Marques, Ricardo
Nascimento, Isabel
Raimundo, Luísa
Portugal, Jorge
Costa, Paulo Matos
author_role author
author2 Marques, Ricardo
Nascimento, Isabel
Raimundo, Luísa
Portugal, Jorge
Costa, Paulo Matos
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Borges, Filipe
Marques, Ricardo
Nascimento, Isabel
Raimundo, Luísa
Portugal, Jorge
Costa, Paulo Matos
description Background. The ideal surgical strategy to multinodular goiter (MNG) is currently still matter of discussion. Thyroid auto- immunity is a well-known risk factor for hypothyroidism and could play a role in MNG’s physiopathology. Objective. Assess thyroid auto-immunity as a risk factor for MNG recurrence. Materials and Methods. Retrospective analysis of a 5-year (January 2012 – December 2016) prospective database of all patients submitted to hemythyroidectomy for MNG. Variables: age, gender, preoperative diagnosis, anti-peroxidase and anti-thyroglobulin antibodies (anti-TPO and anti-Tg); postoperative L-thyroxin therapy, MNG recurrence, contralateral thyroidectomy. MNG recurrence was defined as the need for complementary contralateral lobectomy, or the appearance of new nodules, or an increase in size of at least 50% of the nodules in the remnant lobe. Results. 82 patients included. Median follow-up time of 49 months [33 –88]. Thyroid auto-immunity (anti-TPO and/or anti-Tg) was present in 26% of the patients. 39% of the patients required replacement postoperative L-thyroxin therapy. Recurrence of MNG was observed in 15,2% of the patients but none required contralateral thyroidectomy. Univariate analysis did not show a statistical significant relationship between thyroid autoimmunity and MNG recurrence (p – 0, 461). Discussion / Conclusion. Thyroid autoimmunity dos not seem to represent a risk factor for MNG recurrence after hemythyroidectomy. This surgical approach was effective, with a low recurrence rate. Also the clinical impact of such recurrence was low with no patient needing contralateral resection.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-09
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.34635/rpc.862
https://doi.org/10.34635/rpc.862
url https://doi.org/10.34635/rpc.862
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://revista.spcir.com/index.php/spcir/article/view/862
https://revista.spcir.com/index.php/spcir/article/view/862/646
dc.rights.driver.fl_str_mv Copyright (c) 2022 Revista Portuguesa de Cirurgia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Revista Portuguesa de Cirurgia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Cirurgia
publisher.none.fl_str_mv Sociedade Portuguesa de Cirurgia
dc.source.none.fl_str_mv Revista Portuguesa de Cirurgia; No 53 (2022): December 2022; 23-26
Revista Portuguesa de Cirurgia; No 53 (2022): December 2022; 23-26
2183-1165
1646-6918
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138183933329409